GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (FRA:AJ8) » Definitions » Price-to-Funds-From-Operations

Agenus (FRA:AJ8) Price-to-Funds-From-Operations : (As of May. 24, 2024)


View and export this data going back to . Start your Free Trial

What is Agenus Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Agenus (FRA:AJ8) Business Description

Industry
Traded in Other Exchanges
Address
3 Forbes Road, Lexington, MA, USA, 02421
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).